JKJulian Kleine-Borgmann

Julian Kleine-Borgmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julian Kleine-Borgmann has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Ulrike Bingel

    Department of Neurology, Center for Translational Neuro‐ and Behavioral Sciences University Hospital Essen Essen Germany

    10 shared publications
  • Katharina Schmidt

    Center for Translational Neuro- and Behavioral Sciences, Department of Neurology, University Hospital Essen, Essen, Germany

    9 shared publications
  • Ulrike Bingel

    Department of Neurology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen

    8 shared publications
  • Katharina Schmidt

    Department of Neurology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen

    7 shared publications
  • Harald Engler

    Institute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, Essen, Germany

    3 shared publications
  • Katarina Forkmann

    Department of Neurology, Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

    3 shared publications

Latest Publications

  • Open Access

    Methodological considerations for designing and conducting open-label placebo trials

    by Helena Hartmann, Diana Müßgens, Livia Asan, Aleksandrina Skvortsova, Julian Kleine-Borgmann, Katharina Schmidt, Aurore Fernandez, Jules Phalip, Johannes Wessels, Marco Valerio, et al.

    In pain and other research fields, placebos have traditionally been associated with deception, although harnessing placebo effects does not necessarily require deception. Open-label placebos (OLPs) represent a novel approach in which inert treatments are administered openly and transparently, allowing patients to knowingly receive an inert treatment while still experiencing therapeutic benefits (eg, pain relief). As OLP research grows, concerns have been raised regarding methodological rigor and the unique challenges posed by unblinded designs in both experimental and clinical contexts. Given the inherent transparency regarding treatment group allocation in OLP trials, particular attention is needed when defining appropriate control groups, implementing feasible blinding strategies, and providing a treatment rationale to adequately explain OLPs. Addressing these challenges is crucial to advancing both the scientific understanding of the psychoneurobiological mechanisms underlying OLP effects and their clinical relevance in pain. In this review, we outline key methodological considerations for designing and conducting OLP studies in pain research and beyond, providing guidance on control group selection, blinding strategies, and reporting standards. In addition, we integrate insights from the patient advisory board of the transregional Collaborative Research Center (CRC/TRR) 289 “Treatment Expectation” to incorporate patient perspectives on the feasibility and acceptability of OLPs. Aligning study designs with patient needs and expectations may foster a more meaningful, patient-centered approach to OLP research. By combining methodological guidance and emphasizing patient-centered insights, this review aims to enhance the quality, relevance, and clinical translation of OLP research in pain.

  • Open Access

    Beyond concealment: Translating placebo research into migraine care

    by Julian Kleine‐Borgmann, Katharina Schmidt, Ulrike Bingel

  • Open Access

    Unraveling nocebo effects in visceral pain: negative suggestion and adverse treatment experience uniquely shape visceral pain unpleasantness

    by Jana Luisa Aulenkamp, Robert Jan Pawlik, Catrin Guddat, Harald Engler, Julian Kleine-Borgmann, Adriane Icenhour, Sigrid Elsenbruch

    Visceral pain, characterized by its diffuse, poorly localized, and fear-inducing nature, may be especially prone to nocebo effects. This preregistered experimental study investigated whether (1) visceral pain is more susceptible to nocebo effects than somatic pain, and whether (2) an adverse treatment experience in the somatic modality contributes to visceral nocebo effects by cross-modal generalization. A total of 101 healthy volunteers received inert treatment and were randomized into 4 experimental groups: negative treatment suggestions, adverse somatic treatment experience, their combination, or control. Individually calibrated visceral (rectal distension) and somatic (thermal) pain stimuli were applied. Negative suggestions involved heightened pain sensitivity suggestions; adverse treatment experience was modeled by covertly amplifying thermal pain. Pain ratings, cortisol levels, and emotional states were assessed across pre-, treat-, and test-phases, and upon re-exposure to pain 1 week later. Negative suggestions increased negative expectations and cortisol levels, and the thermal pain manipulation successfully amplified somatic pain during treatment ( P < 0.001). In the test-phase, both suggestions and somatic experience independently increased visceral pain unpleasantness ( P = 0.004; P = 0.011), whereas no somatic nocebo effects emerged. No group differences appeared at re-exposure, but perceived treatment allocation was influenced both by suggestions and experience. Findings support the distinct vulnerability of the visceral modality to nocebo effects, which can arise or intensify through cross-modal transfer from adverse somatic treatment experiences, emphasizing the importance of provider communication and consideration of prior experiences in the treatment of chronic visceral pain conditions, especially in patients with mixed pain phenotypes.


  • Open Access

    Open-Label Placebos as Adjunct for the Preventive Treatment of Migraine

    by Julian Kleine-Borgmann, Katharina Schmidt, Linda Ludwig, Moritz Schulz, Dagny Holle-Lee, Charly Gaul, Ulrike Bingel

    Importance: Placebo effects contribute substantially to the therapeutic success of many treatments, particularly in pain-related conditions. Open-label placebos (OLPs) offer an ethically acceptable approach to harness this potential without deception.Objective: To evaluate the efficacy of a 3-month OLP regimen in reducing headache and migraine days and improving migraine-related outcomes, including medication use, disability, and quality of life, in patients with migraine.Design, Setting, and Patients: This controlled, bicenter, parallel-group randomized clinical trial, with a 3-month treatment phase, enrolled adults with episodic or chronic migraine between November 9, 2020, and November 1, 2022. The trial was conducted at 2 tertiary headache centers in Germany (University Medicine Essen and Headache Center Frankfurt).Interventions: Participants received OLPs plus treatment as usual (TAU) or TAU alone. OLPs were administered twice daily for 3 months.Main Outcomes and Measures: The preregistered primary outcome was the change in monthly headache days from a baseline to a test period after 3 months. Secondary outcomes included patient-reported quality of life assessed using the 12-Item Short-Form Health Survey physical component summary, pain-related disability assessed using the Pain Disability Index and Headache Impact Test, and global improvement.Results: Of the 120 patients (median age, 34.2 years; 95% CI, 29.8-39.3 years; 103 [86%] female), 102 (85%) had episodic migraine, and 18 (15%) had chronic migraine. All participants completed the study. Headache days did not significantly decrease in the OLP group compared with TAU. Similarly, there was no difference in the number of migraine days, pain intensity, days of rescue medication, and the 50% responder rate. However, OLP-treated patients reported improved quality of life (β = 4.25; 95% CI, 1.33-7.17; d = 0.47; P = .01), reduced pain-related disability (Pain Disability Index: β = −5.96; 95% CI, −9.01 to −2.92; d = 0.53; P < .001; Headache Impact Test 6: β = −1.88; 95% CI, −3.28 to −0.48; d = 0.35; P = .02), and higher global improvement (χ2 = 14.16; P = .01) compared with TAU patients.Conclusions and Relevance: In this randomized clinical trial, OLP treatment did not reduce headache frequency but was associated with improvements in quality of life and pain-related disability. Future research should clarify the mechanisms underlying these effects and determine their potential supportive role in migraine care for selected patients.Trial Registration: drks.de identifier: DRKS00021259


  • Open Access

    From catastrophizing to catalyzing: does pain catastrophizing modulate the beneficial impact of open-label placebos for chronic low back pain? A secondary analysis

    by Elif Buse Caliskan, Katharina Schmidt, Andreas Hellmann, Tamás Spisák, Ulrike Bingel, Julian Kleine-Borgmann, Tam

    Chronic back pain (CBP) is a global health problem with significant health and economic consequences. Traditional analgesics are often no better than placebo, highlighting the need for biopsychosocial approaches. Open-label placebos (OLPs), administered with patient consent, offer a promising alternative. Existing research has mainly focused on the effects of OLP treatments on patient-reported outcomes. In a previous randomized controlled trial (RCT), we investigated whether an OLP treatment improves subjective and objective outcomes such as spinal mobility in CBP patients. The analysis showed significant reductions in pain intensity, disability, and depressive symptoms after OLP combined with treatment-as-usual (TAU). However, objective improvements in spinal mobility were not observed. In this exploratory analysis, we aimed to identify predictors of objective improvement after OLP treatment. Psychological factors (e.g., depression, stress, and pain catastrophizing) and baseline physiological measures were analyzed using generalized linear models. Results showed that patients with lower pain catastrophizing exhibited increased spinal motion velocity in the OLP+TAU group, while those with higher pain catastrophizing did not. These findings suggest that OLP treatment may provide measurable benefits for a specific subset of patients, supporting its potential as a personalized intervention in managing CBP. Further research is needed to confirm these findings and to elucidate the role of psychological factors in chronic pain management.


  • Open Access

    Setting the stage for pain relief: how treatment setting impacts interdisciplinary multimodal pain treatment for patients with chronic back pain

    by Dustin Maser, Diana Müßgens, Julian Kleine-Borgmann, Balint Kincses, Katharina Schmidt, Sigrid Elsenbruch, Daniel Müller, Ulrike Bingel

    While interdisciplinary multimodal pain treatment (IMPT) is an effective treatment option for chronic low back pain, it is usually accomplished as an inpatient treatment incurring substantial healthcare costs. Day hospital IMPT could be a resource-saving alternative approach, but whether treatment setting is associated with differences in treatment outcomes has not yet been studied. In a retrospective matched cohort study including data from N = 595 patients diagnosed with chronic back pain and undergoing IMPT at the back pain center in Essen, Germany, we investigated the association between treatment setting (ie, inpatient or day patient of an otherwise identical IMPT) and pain intensity, disability, and self-efficacy after treatment. Outcomes were assessed by questionnaires used in clinical routine, collected at pre-IMPT, post-IMPT, and at 3-, 6-, and 12-month follow-up. The results indicate that day patients showed greater improvements in pain-related disability at 3-month post-IMPT (d = 0.74) and in pain intensity at 6-month post-IMPT (d = 0.79), compared to a matched sample of inpatients. Moreover, day patients achieved higher scores in pain-related self-efficacy at discharge, 3- and 6-month post-IMPT (d = 0.62, 0.99, and 1.21, respectively) and reported fewer incapacity-for-work days than inpatients at 6-month post-IMPT (d = 0.45). These data suggest that day hospital IMPT can be as effective as inpatient treatment and might even be more effective for the less afflicted patients. Further research regarding treatment setting and indication could guide optimized and cost-efficient treatments that are more closely tailored to the individual patient's needs.


  • Open Access

    Hydrocortisone Differentially Affects Reinstatement of Pain-related Responses in Patients With Chronic Back Pain and Healthy Volunteers

    by Katharina Schmidt, Frederik Schlitt, Katja Wiech, Christian J. Merz, Julian Kleine-Borgmann, Oliver T. Wolf, Harald Engler, Katarina Forkmann, Sigrid Elsenbruch, Ulrike Bingel


  • Open Access

    Open-label placebo treatment does not enhance cognitive abilities in healthy volunteers

    by Helena Hartmann, Katarina Forkmann, Katharina Schmidt, Julian Kleine-Borgmann, Johanna Albers, Katja Wiech, Ulrike Bingel

    The use of so-called ‘smart drugs’ such as modafinil to improve cognitive performance has recently attracted considerable attention. However, their side effects have limited user enthusiasm. Open-label placebo (OLP) treatment, i.e., inert treatments that are openly disclosed to individuals as having no active pharmacological ingredient, has been shown to improve various medical symptoms and conditions, including those related to cognitive performance. OLP treatment could therefore be an exciting alternative to pharmacological cognitive enhancers. Here, we used a randomized-controlled design to investigate the effect of a 21-day OLP treatment on several sub-domains of cognitive performance inN = 78 healthy volunteers. Subjective and objective measures of cognitive performance as well as different measures of well-being were obtained before and after the treatment period. Using a combination of classic Frequentist and Bayesian analysis approaches showed no additional benefit from OLP treatment in any of the subjective or objective measures of cognitive performance. Our study thus highlights possible limitations of OLP treatment in boosting cognitive performance in healthy volunteers. These findings are discussed in the light of expectancy-value considerations that may determine OLP efficacy.


  • Open Access

    No long-term effects after a 3-week open-label placebo treatment for chronic low back pain: a 3-year follow-up of a randomized controlled trial

    by Julian Kleine-Borgmann, Tim-Niklas Dietz, Katharina Schmidt, Ulrike Bingel

    Chronic low back pain is prevalent, highly disabling, and a relevant socioeconomic health concern. Although allocated to placebo groups, patients in randomized controlled trials show significant pain relief, pointing to the relevance of placebo effects. Overcoming ethical and legal concerns related to deceptive placebos, recent studies have demonstrated the efficacy of short-term treatments for chronic low back pain with open-label (ie, nondeceptive) placebos. However, data on long-term efficacy of open-label placebos are sparse. Here, we report a 3-year follow-up of our previously published randomized controlled trial demonstrating pain reduction, improvement in disability, and depressive symptoms after a 3-week treatment with open-label placebos. Including records from 89 previously enrolled patients, we investigated changes between the groups with and without previous open-label placebo treatment in pain intensity (primary outcome), disability and mood (secondary outcomes), biopsychosocial factors and lifestyle (exploratory outcomes) from parent baseline to follow-up. Over the 3-year period, there were no differences in any outcome between groups with and without open-label placebo treatment. Therefore, our follow-up data do not support the previously suggested assumption that a 3-week open-label placebo treatment has long-term effects. This study was preregistered on April 14, 2020, in the German Clinical Trials Register (registration number DRKS00021405).


  • Open Access

    Greater interruption of visual processing and memory encoding by visceral than somatic pain in healthy volunteers – An fMRI study

    by Katharina Schmidt, Julian Kleine-Borgmann, Katrin Scharmach, Diana Müssgens, Sigrid Elsenbruch, Ulrike Bingel, Katarina Forkmann